Tandem Diabetes Care (TNDM) Receivables (2013 - 2026)

Tandem Diabetes Care's Receivables history runs 14 years deep, the most recent figure standing at $140.7 million for Q1 2026.

• Quarterly Receivables rose 11.15% year-over-year to $140.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $140.7 million (up 11.15% YoY) and the FY2025 annual result came in at $173.9 million, up 51.75% from the prior year.
• Receivables was $140.7 million for Q1 2026 at Tandem Diabetes Care, down from $165.5 million in the prior quarter.
• Across five years, Receivables topped out at $165.5 million in Q4 2025 and bottomed at $93.0 million in Q1 2024.
• A 5-year average of $114.9 million and a median of $112.8 million in 2022 frame the typical range for Receivables.
• Annual changes were most pronounced in 2023 — Receivables fell 7.99% — and 2025, when it jumped 44.43%.
• Tandem Diabetes Care's Receivables stood at $114.7 million in 2022, then slipped by 7.99% to $105.6 million in 2023, then advanced by 8.55% to $114.6 million in 2024, then jumped by 44.43% to $165.5 million in 2025, then dropped by 15.0% to $140.7 million in 2026.
• Business Quant data shows TNDM's Receivables at $140.7 million in Q1 2026, $165.5 million in Q4 2025, and $125.9 million in Q3 2025.